open access

Vol 13, No 5 (2009)
Prace oryginalne
Published online: 2009-12-04
Get Citation

Fibrinolysis in hypertensive patients with glomerulonephritis

Jolanta Małyszko, Jacek S. Małyszko, Michał Myśliwiec, Tetsumei Urano
Nadciśnienie tętnicze 2009;13(5):336-340.

open access

Vol 13, No 5 (2009)
Prace oryginalne
Published online: 2009-12-04

Abstract


Background The role of fibrinolysis and serotonin in glomerulonephritis is still the matter of controversy. In essential hypertension fibrinolytic activity is diminished. The aim of the study was to assess some fibrinolytic parameters, in patients with glomerulonephritis in relation to healthy volunteers.
Material and methods Hypertensive patients with biopsyproven glomerulonephritis and normal renal function were treated for three months with nitrendipine (40 mg/day) (n = 18) or enalapril (20 mg/day) (n = 16). Healthy volunteers served as a control group. Activities of tPA and PAI-1 (amidolytic method), concentrations of tPA, PAI and tPA/PAI complexes (EIA) were studied by means of commercially available kits (Spectrolyse, Biopool, Sweden, Technoclone, Austria, respectively). Euglobulin clot lysis time (ECLT) was measured according to Kowarzyk and Buluk.
Results Diminished activity of tPA and a significant prolongation of ECLT was observed in hypertensive patients with glomerulonephritis when compared to healthy volunteers (p < 0.05). Concentration and activity of PAI were found to be higher in hypertensive patients when compared to the control group (p < 0.01). After 3 months of treatment with enalapril PAI concentration and activity decreased significantly, whereas in nitrendipine group a rise in tPA concentration was seen.
Conclusions Impairment in fibrinolysis in glomerulonephritis in hypertensive patients, may contribute to the increased risk of thromboembolic complications and accelerated atherosclerosis observed in these patients. Hypertensive treatment may favourably affect fibrinolysis in these patients.

Abstract


Background The role of fibrinolysis and serotonin in glomerulonephritis is still the matter of controversy. In essential hypertension fibrinolytic activity is diminished. The aim of the study was to assess some fibrinolytic parameters, in patients with glomerulonephritis in relation to healthy volunteers.
Material and methods Hypertensive patients with biopsyproven glomerulonephritis and normal renal function were treated for three months with nitrendipine (40 mg/day) (n = 18) or enalapril (20 mg/day) (n = 16). Healthy volunteers served as a control group. Activities of tPA and PAI-1 (amidolytic method), concentrations of tPA, PAI and tPA/PAI complexes (EIA) were studied by means of commercially available kits (Spectrolyse, Biopool, Sweden, Technoclone, Austria, respectively). Euglobulin clot lysis time (ECLT) was measured according to Kowarzyk and Buluk.
Results Diminished activity of tPA and a significant prolongation of ECLT was observed in hypertensive patients with glomerulonephritis when compared to healthy volunteers (p < 0.05). Concentration and activity of PAI were found to be higher in hypertensive patients when compared to the control group (p < 0.01). After 3 months of treatment with enalapril PAI concentration and activity decreased significantly, whereas in nitrendipine group a rise in tPA concentration was seen.
Conclusions Impairment in fibrinolysis in glomerulonephritis in hypertensive patients, may contribute to the increased risk of thromboembolic complications and accelerated atherosclerosis observed in these patients. Hypertensive treatment may favourably affect fibrinolysis in these patients.
Get Citation

Keywords

fibrinolytic system; hypotensive therapy; atherosclerosis

About this article
Title

Fibrinolysis in hypertensive patients with glomerulonephritis

Journal

Arterial Hypertension

Issue

Vol 13, No 5 (2009)

Pages

336-340

Published online

2009-12-04

Bibliographic record

Nadciśnienie tętnicze 2009;13(5):336-340.

Keywords

fibrinolytic system
hypotensive therapy
atherosclerosis

Authors

Jolanta Małyszko
Jacek S. Małyszko
Michał Myśliwiec
Tetsumei Urano

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl